Merck & Co., Inc. Q3 FY2026 results
$147.76+0.55%
Merck & Co., Inc. reported revenue of $18.1 billion, up 4.7% from a year earlier, net income of $5.07 billion and diluted earnings per share of $2.04 against $2.32 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, the results first announced on 29 Oct 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $18.09B | $17.28B | +4.7% |
| Gross profit | $13.19B | $13.42B | −1.7% |
| Gross margin | 72.9% | 77.7% | −4.7 pts |
| Operating income | $6.11B | $7.07B | −13.7% |
| Operating margin | 33.8% | 40.9% | −7.2 pts |
| Net income | $5.07B | $5.79B | −12.4% |
| Diluted EPS | $2.04 | $2.32 | −12.1% |
| Operating cash flow | $6.56B | $7.82B | −16.2% |
| Capital expenditure | $1.04B | $987.0M | +5.4% |
| Free cash flow | $5.52B | $6.83B | −19.3% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Keytruda revenue | $7.8B | down 4.6% |
| Gardasil/Gardasil 9 revenue | $2.0B | up 14.1% |
| Livestock revenue | $1.0B | up 2.4% |
| Keytruda Qlex revenue | $830.0M | — |
| ProQuad/M-M-R II/Varivax revenue | $730.0M | up 6.7% |
| Winrevair revenue | $694.0M | up 92.8% |
| Companion Animal revenue | $628.0M | up 6.1% |
| Lynparza alliance revenue | $352.0M | down 7.1% |
| Prevymis revenue | $347.0M | up 30.5% |
| Welireg revenue | $307.0M | up 56.6% |
| Lenvima alliance revenue | $287.0M | up 11.2% |
| Capvaxive revenue | $263.0M | up 7.8% |
| RotaTeq revenue | $196.0M | down 3.9% |
| Vaxneuvance revenue | $195.0M | down 13.7% |
| Janumet revenue | $194.0M | down 20.2% |
| Januvia revenue | $186.0M | down 51.3% |
| Ohtuvayre revenue | $184.0M | — |
| Reblozyl alliance revenue | $177.0M | up 30.1% |
| Bridion revenue | $144.0M | down 67.2% |
| Adempas/Verquvo alliance revenue | $118.0M | up 5.4% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $18.09B | +4.7% | $2.04 |
| Q2 FY2026 | 30 Jun 2026 | $16.61B | +5.1% | −$0.54 |
| Q1 FY2026 | 31 Mar 2026 | $16.29B | +4.9% | −$1.72 |
| Q4 FY2025 | 31 Dec 2025 | $16.40B | +5.0% | $1.19 |
| Q3 FY2025 | 30 Sep 2025 | $17.28B | +3.7% | $2.32 |
| Q2 FY2025 | 30 Jun 2025 | $15.81B | −1.9% | $1.76 |
| Q1 FY2025 | 31 Mar 2025 | $15.53B | −1.6% | $2.01 |
| Q4 FY2024 | 31 Dec 2024 | $15.62B | +6.8% | $1.48 |
More on Merck & Co., Inc.: financial statements · revenue · earnings per share
MRK's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
